Articles related to SKIN CANCER
Terry Bradshaw’s Merkel Cell Carcinoma
The Hall-of-Fame quarterback recently alerted worried viewers about the diagnosis of the rare disease after he felt some pain in his neck. Ultimately, the diagnosis changed his outlook on life. “We’re going to go to Europe, going to go to Paris, going to go to wherever we want to go. I’m going to get all this in because I feel like I don’t want to put this off anymore … I may have 25, 30 years left, but I’m going to act like I got one.” Terry Bradshaw
Dermatology November 28th 2022
The New England Journal of Medicine
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neoadjuvant cemiplimab was administered to a total of 79 individuals. Upon independent review, a pathological complete response (51 percent; 95% confidence interval [CI], 39 to 62) was noted in 40 patients, and a pathological substantial response (13 percent; 95% CI, 6 to 22) was noted in 10 patients. These outcomes matched the abnormal reactions identified during the investigator’s examination. Fifty-four (54) patients (68%; 95% CI, 57 to 78) had an objective response on imaging, and 69 individuals (87%) experienced adverse events of any grade that happened throughout the course of the study, regardless of whether they were linked to the study treatment. Fourteen (14) participants (18%) experienced adverse events of grade 3 or higher during the research period.
Dermatology October 31st 2022
Adjuvant Therapy of Nivolumab Combined with Ipilimumab vs. Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.
Oncology, Medical October 3rd 2022
DermDx: Crusted, Bleeding Patch on Forehead
A 70-year-old woman with a skin lesion on her right temple is referred for assessment. She claims that the site originally came to light about a year ago and has grown in size ever since. An erythematous, fibrotic plaque with a depressed center is discovered during examination. What is the most likely cause of the lesion?
Dermatology September 20th 2022
Tumor-Infiltrating Lymphocytes Outperform Ipilimumab in Advanced Melanoma
168 adults with unresectable stage IIIC-IV melanoma with progression after 1 line of systemic treatment (not including ipilimumab) were randomly assigned to receive tumor-infiltrating lymphocyte therapy or ipilimumab. With a median follow-up of nearly 3 years, the median PFS was 7.2 months in the TIL arm and 3.1 months in the ipilimumab arm.
Oncology, Medical September 12th 2022